

Patent Application

Attorney Docket No. PC28053

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, Box 1450, P.O. Box 1450, Alexandria, VA 22313-1450 on this 10 day of May, 2004.

By

(Signature of person mailing)

Andrea E. Dorigo

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Amidon et al. :

APPLICATION NO.: 10/626,166 : Examiner:

FILING DATE: July 25, 2002 : Group Art Unit: 1614

TITLE: SUSTAINED-RELEASE TABLET :
COMPOSITION OF PRAMIPEXOLE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.


Respectfully submitted,

Date: 5/10/04




Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC28053				SERIAL NO. 10/626,166			
										APPLICANT Amidon et al.							
										FILING DATE July 25, 2002				GROUP 1614			
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	a)	6	2	7	7	8	7	5	8/21/01	Holman, Andrew J.	514	367					
	b)	4	7	3	1	3	7	4	3/15/88	Griss et al.	514	367					
	c)	0	0	1	5	7	3	5	2/7/02	Hedden et al.	424	488					
	d)	6	0	5	6	9	7	7	5/2/00	Bhagwat et al.	424	488					
	e)	5	4	7	2	7	1	2	12/5/95	Oshlack et al.	424	480					
	f)	6	1	9	7	3	3	9	3/6/01	Ju, Tzu-chi Robert	424	468					
	g)	5	4	5	8	8	8	7	10/17/95	Chen et al.	424	464					
	h)	5	6	5	6	2	9	6	8/12/97	Khan et al.	424	473					
	i)	2	8	8	7	4	4	0	5/19/59	Greminger et al.	167	82					
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
													YES	NO			
	j)	0	1	2	2	8	2	0	4/5/01	WO	A01N	43/78					
	k)	9	9	1	6	4	4	2	4/8/99	WO	A61K						
	l)	9	9	0	9	0	6	6	2/25/99	WO	C08B	A61K					
	m)	9	9	4	5	9	2	4	9/16/99	WO	A61K						
	n)	0	9	3	3	0	7	9	1/26/99	EPC	A61K	C08B					
	o)	0	0	5	9	4	7	7	10/12/00	WO	A61K						
	p)	9	7	0	4	7	5	2	2/13/97	WO	A61K						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
	q)	Physicians' Desk Reference 57th edition (2003), 2768-2772															
	r)	Hiestand & Smith (1984), Powder Technology 38, 145-159															
	s)	Hiestand & Smith (1991), International Journal of Pharmaceutics 67, 231-246															
	t)	Hubble et al. (1995), Clinical Neuropharmacology 18(4), 338-347															
	u)	Dooley & Markham (1998), Drugs & Aging 12(6), 495-514															
	v)	Biglan & Holloway (2002), Expert Opinion on Pharmacotherapy 3(2), 197-210															



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC28053		SERIAL NO. 10/626,166		
		APPLICANT Amidon et al.				
		FILING DATE July 25, 2002		GROUP 1614		
	w)		Wright et al. (1997), <i>Journal of Clinical Pharmacology</i> 37, 520–525			
	x)		United States Pharmacopeia 24th edition (2000) (USP 24), pp. 1941–1943			
	y)		Colosimo & De Michele (1999), <i>European Journal of Neurology</i> 6(1), 1–21			
EXAMINER						
DATE CONSIDERED						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE